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NOVEL APPLICATION OF UNTARGETED METABOLOMICS TO DISEASE OF
NEUROSURGICAL SIGNIFICANCE. Alex Y. Lu, Tore Eid, Veronica L. Chiang, Ketan R. Bulsara.
Department of Neurosurgery, Yale School of Medicine, New Haven, CT.

Metabolomics, an emerging technique to study hundreds of small-molecule metabolites simultaneously, has
been seldom applied to diseases of neurosurgical significance. We utilized metabolomics to explore two
distinct questions: 1. to identify global metabolic changes and metabolite predictors of long-term outcome
in aneurysmal subarachnoid hemorrhage (SAH) patients, 2. to identify differential metabolites profiles of
radiation necrosis vs. recurrent tumor of metastatic brain lesions post-Gamma Knife radiosurgery. The first
study applied gas chromatography time-of-flight mass spectrometry (GC-TOF) to cerebrospinal fluid
samples collected from 15 high-grade aSAH patients (modified Fisher grades 3 and 4). Analysis was
performed at two time points; metabolite levels at each time point were correlated with Glasgow Outcome
Scale (GOS) of patients at 1 year post-aSAH. Of 97 metabolites identified, 16 metabolites (primarily free
amino acids) significantly changed between the two time points; these changes were magnified in modified
Fisher grade 4 compared with grade 3. Six metabolites (2-hydroxyglutarate, tryptophan, glycine, proline,
isoleucine, and alanine) correlated with GOS at 1 year post-aSAH. These results suggest that specific
metabolite changes occur in the brain during the course of aSAH and that quantification of specific CSF
metabolites may be used to predict long-term outcomes. This is the first study to implicate 2hydroxyglutarate, a known marker of tissue hypoxia, in aSAH pathogenesis. The second study applied GCTOF to histologically-validated specimens (7 each) of pure radiation necrosis and pure recurrent tumor
obtained from patient brain biopsies. Of 141 metabolites identified, 17 were found to be statistically
significantly different between comparison groups. Of these metabolites, 6 were increased in tumor, and 11
metabolites were increased in radiation necrosis. An unsupervised hierarchical clustering analysis found
that tumor had elevated levels of metabolites associated with energy metabolism whereas radiation necrosis
had elevated levels of metabolites that were fatty acids and antioxidants/cofactors. This is the first tissuebased metabolomics study of radiation necrosis and tumor. Radiation necrosis and recurrent tumor
following Gamma Knife radiosurgery for brain metastases have unique metabolite profiles that may be
targeted in the future to develop non-invasive metabolic imaging techniques.
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Introduction
The Emergence of Metabolomics
During the last quarter century, the technology to investigate molecular
mechanisms has rapidly evolved. Genomics and proteomics, the study of genome and set
of proteins expressed by a genome respectively, have established themselves as leading
fields of scientific inquiry. However, the study of genes and proteins without respect to
downstream primary and secondary metabolites that they alter is limited. For example,
when examining the most prevalent chronic diseases such as diabetes and cardiovascular
pathology, the largest of genome-wide association studies only have described a modest
fraction of these diseases and have provided partial insight mechanism-based intervention
strategies1-3.
Metabolites are defined as the small molecules such as amino acids,
carbohydrates, nucleotides, and lipids that are transformed during an organism’s
metabolism. Metabolites can be grouped into several categories. When metabolites are
produced by a host organism, they are considered to be endogenous metabolites whereas
metabolites that originate from diet or the environment are considered exogenous
metabolites. Most endogenous metabolites are also considered primary metabolites,
biochemical compounds that are crucial for normal growth and development of an
organism.
A biological sample’s complete metabolite profile is defined as a metabolome.
Metabolomics, the study of specific metabolomes, reveals a glimpse into the chemical
fingerprint of an organism by identifying and quantitatively measuring hundreds to
thousands of metabolites simultaneously. While humans possess an estimated 25,000
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genes, 100,000 transcripts, and 1,000,000 proteins3, human metabolome is estimated only
to contain around 6,500 discrete small molecule metabolites4. While genes and proteins
are modulated by epigenetic regulation and post-translational modifications respectively,
metabolites represent the direct signatures of biochemical activity and therefore better
correlate with an organism’s state-specific phenotype5. This combination of these
benefits makes metabolomics an ideal tool for clinical diagnostics as well as drug
discovery.
Metabolomics can be divided into two general study types: targeted and
untargeted. Targeted metabolomics is defined as the study of a specific number of
predetermined metabolites. The work flow of targeted metabolomics originates with a
hypothesis regarding the role or function of a predetermined metabolite within a
predetermined biochemical pathway. With this approach, targeted metabolomics is
particularly effective when applied to pharmacokinetic studies of drug metabolism and
influence of genetic modifications or therapeutics on specific enzymes6. However,
targeted metabolomics studies can only validate hypotheses and are limited when
attempting elucidate novel molecular pathways. By comparison, untargeted
metabolomics attempts to measure as many metabolites simultaneously as possible;
however, this method provides limited control of what types of metabolites will be
measured. Therefore, untargeted metabolomics provides global metabolite profiles,
providing insight to biological processes that may have been previously uncharacterized.
As a result, untargeted metabolomics is tool for hypothesis generation rather than
hypothesis validation like that of targeted metabolomics.
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The techniques to conduct metabolomics have rapidly evolved over the past
decade. The workflow to generate and analyze metabolomics datasets are uniform: data
acquisition, metabolite identification, and statistical analysis. Until the mid-2000s,
nuclear magnetic resonance was the method of choice for the data acquisition and
metabolite identification steps due to its highly accurate readings; however, nuclear
magnetic resonance’s limited metabolite sensitivity and specificity precluded global
metabolite profiling. The current gold standard for metabolomics is mass spectrometry
preceded by chromatographic separation (usually gas or liquid chromatography) to
separate the highly complex mixture of metabolites in biological samples using the
different chemical and physical properties of metabolites. Liquid chromatography uses a
liquid mobile phase and is performed at room temperatures whereas gas chromatography
utilizes a gas mobile phase and is performed at higher temperatures. Liquid
chromatography has the advantage of being non-destructive to analyzed samples and can
measure metabolites that are thermally labile. Gas chromatography can be performed
faster, has higher resolutions, and provides higher peak resolution compared to liquid
chromatography while also being less expensive to perform.
Mass spectrometry is advantageous compared to nuclear magnetic resonance due
to its high sensitivity, reproducibility and versatility7. When a sample is processed,
chromatographic separation yields a retention time for each unique metabolite. The
masses of these metabolites and subsequent compound fragments are then measured by
mass spectrometry, generating a mass-to-charge ratio. The combination of retention time
and mass-to-charge ratio allows for the identification of thousands of metabolites
simultaneously when compared to a standardized library of metabolite. In addition, mass
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spectrometry generates relative intensities for each metabolite, allowing for quantification
of metabolite levels. Many different mass spectrometry methods exist, each tailored for
specific purposes. While triple quadrupole (QqQ) mass spectrometry is used for targeted
metabolomics due to its high chemical sensitivity and specificity, quadrupole time-offlight (Q-TOF) mass spectrometry is the method of choice for untargeted metabolomics
studies.
Statistical analysis can be one of the most challenging aspects of conducting
metabolomics. While targeted metabolomics can utilize workflows optimized to a priori
knowledge of specific metabolites and metabolic pathways of interest, untargeted
metabolomics generates complex data sets that require advanced computational tools to
identify metabolite differences between samples and to examine each metabolite’s
relation to metabolic pathways and aberrant processes7. Some of these computational
tools include multivariate statistical techniques (principal component analysis, partial
least squares regression) and machine learning techniques (random forest, hierarchical
clustering).
Because metabolomics techniques have existed for only the past two decades,
several limitations exist. While many compounds can be detected using current
technologies, many of the detected mass spectroscopy spectra have yet to be correlated to
metabolites with known chemical structures. One study suggested that only 25% of
observed compounds have been identified8. In addition, untargeted metabolomics can
only provide relative quantification of metabolite levels and thus does not give
measurement in SI units.
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The applications of metabolomics have been diverse and is increasingly growing.
Research areas that have utilized metabolomics have included plant biology9, nutrition10,
and winemaking11. Within medicine, the bulk of metabolomics studies have focused on
discovering and validating biomarkers within the fields of cancer12, psychiatric disease13,
and microbiome14. The studies presented in this thesis utilize untargeted metabolomics
due to its ability to identify novel metabolites/pathways and represent some of the first
published studies to utilize untargeted metabolomics within issues of neurosurgical
interest.

Subarachnoid Hemorrhage
Despite advancements in medical and surgical therapies, the clinical outcomes of
aneurysmal subarachnoid hemorrhage (aSAH) have remained poor. Morbidity and
mortality from subarachnoid hemorrhage and resulting complications are unacceptably
high. Case fatality rate has been reported to be as high as 50%15; of those who survive, up
to 40% of patients will suffer from long-term delayed neurological deficits such as stroke,
hydrocephalus, and other ischemia-related disease16. These issues demonstrate the need
for prognostic biomarkers that may better direct patient care. Although some potential
biomarkers have been identified using human serum, cerebrospinal fluid, and urine, none
are used clinically.
Cerebral vasospasm of large caliber vessels typically occurs between days 3 and
14 post-subarachnoid hemorrhage and has been thought to be a major contributor to
morbidity and mortality; thus, cerebral vasospasm has been the historic target of
intervention and biomarker identification studies. Around two-thirds of patients will
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demonstrate some form (clinical vs. radiographic) of cerebral vasospasm during the postsubarachnoid hemorrhage period17. Current monitoring techniques includes frequent
neurological examinations, transcranial Doppler ultrasonography, and computed
tomography angiography (CTA) to examine changes in neurological status and vessel
caliber. Therapies include oral or intra-arterial calcium channel blockers such as
nimodipine, triple-H therapy (inducing hypertension, hypervolemia, and hemodilution),
and balloon angioplasty. However, because cerebral vasospasm is a heterogeneous
disease process combining pathology such as increased contraction of vascular smooth
muscles cells, formation of microscopic thrombi in distal vessels, and inflammatory
changes18, no cerebral vasospasm biomarkers in serum or cerebrospinal fluid have been
validated.
Recent clinical trials and literature have implicated other pathophysiologic
factors as key contributors to poor patient outcomes of aneurysmal subarachnoid
hemorrhage19,20. These factors include early brain injury, cerebral autoregulation
disruption, electrolyte disturbances, oxidative stress, blood breakdown products, and
inflammatory pathways21. Among these secondary sequaelae of subarachnoid
hemorrhage, no clinical validated biomarkers exist17. Contributing to the lack of
clinically useful biomarkers is the lack of knowledge regarding the pathophysiology of
subarachnoid hemorrhage. Subarachnoid hemorrhage results in the vasculature of the
brain, which is normally surrounded by cerebrospinal fluid (CSF), to be surrounded by a
combination of blood, blood breakdown products, and cerebrospinal fluid. This altered
cerebrospinal fluid and blood mixture triggers a cascade of unknown metabolic events
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that disrupts all three layers of the blood vessels beginning around day 3 after the
aneurysmal subarachnoid hemorrhage22.
The high throughput profiling of metabolites, metabolomics, allows for the
systematic analysis of the unique signature that cellular processes leave behind and can
provide a chemical phenotype to the disease state. The identification of these signatures
have been shown to have predictive and therapeutic value in other disease states23,24. For
example, use of troponin level measurements has been proven to be one of the diagnostic
tests with the highest sensitivity and specificity for acute myocardial infarction. Within
the central nervous system, S100β and neuron-specific enolase as well as cerebrospinal
fluid biomarkers creatinine kinase brain isoenzyme and neurofilament have been
examined within the context of acute brain injury although the results of these studies
have been mixed25.
The aberrant metabolic processes of subarachnoid hemorrhage are currently
unknown. In the first portion of this study, we report the results of applying untargeted
metabolomics using gas chromatography with time-of-flight mass spectrometry (GCTOF) to the cerebrospinal fluid of aneurysmal subarachnoid hemorrhage patients to
determine global metabolic changes and metabolite predictors of long-term outcome in
patient after aneurysmal subarachnoid hemorrhage.

Radiation Necrosis vs. Recurrent Tumor Conundrum
Gamma knife radiosurgery (GKRS) is a highly effective treatment for brain
metastases especially when the tumors are multiple, small and surgically less accessible.
The highly conformal delivery of radiation to the metastases results in relatively little

8
radiation exposure to the surrounding brain and preserves neurological status than the
alterative, whole brain radiation. In a minority of cases, following an initial good
response to GKRS treatment, the tumor being watched using magnetic resonance imaging
(MRI) can start to regrow around 12 months after initial therapy. Radiographically, this
appears as regrowth of the gadolinium-enhancing lesion on T1 weighted imaging
associated with an increase in the amount of surrounding fluid-attenuated inversion
recovery (FLAIR) signal. Histological examination of these re-growing lesions, however,
can show either recurrent tumor or a treatment-related inflammatory process known as
radiation necrosis. Radiation necrosis can be identified on histology by a central zone of
coagulation necrosis surrounded inflammatory demyelination, astrocytosis, vascular
hyalinization and reactive edema26,27.
Despite clear histological differences and extensive research in the area,
distinguishing radiation necrosis from recurrent tumor using non-invasive tests remains
difficult. Currently available techniques for trying to differentiate the two entities include
MR spectroscopy, MR perfusion, MR diffusion, and positron emission tomography
(PET) imaging with tracers such as methionine-PET. While diagnostic accuracy rates of
up to 80% have been reported at dedicated centers, the differentiation remains far from
perfect when used in standard clinical practice. Differentiating the two processes,
however, is vital to patient management decision making. Recurrent tumor may warrant
further radiation treatment while radiation necrosis is typically managed with
corticosteroids and other medical or surgical approaches since re-irradiation may worsen
clinical status. To make the correct diagnosis, the current standard of care remains for
these patients to undergo invasive brain biopsy or resection28, exposing them to avoidable
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surgical and perioperative risks that is also associated with considerable healthcare
spending costs.
Given that radiation necrosis and tumor are distinct cellular processes, it would be
expected that their metabolite profiles should also be distinguishable. The differences in
their metabolite profiles could theoretically be used in conjunction with metabolite-based
imaging to provide non-invasive differentiation of radiation necrosis vs. recurrent. In
Metabolomic profiling using gas chromatography with time-of-flight mass spectrometry
(GC-TOF) analysis allows investigators to evaluate a diverse range of low-molecular
weight metabolites29-31. In this study, we implement GC-TOF on flash-frozen biopsyconfirmed radiation necrosis and tumor following GKRS to identify differential
metabolite levels between the comparison groups and compare the identified metabolites
to those currently used in metabolite-based imaging.

Statement of Purpose
First Study
• To identify global metabolic changes and metabolite predictors of long-term
outcome in the cerebrospinal fluid of post-aneurysmal subarachnoid hemorrhage
patients.
We hypothesize that CSF metabolomics profiles of aSAH patients change during the
course of aSAH in an unknown manner and that these changes can be correlated to
radiographic prognosticators such as the modified Rankin Score and to long term patient
outcomes.
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Second Study
• To identify differential metabolites profiles of radiation necrosis vs. recurrent tumor
of metastatic brain lesions post-Gamma Knife radiosurgery
We hypothesize that the underlying distinctions in pathology between radiation necrosis
and recurrent tumor of brain metastases lead to differential metabolite profiles; the
identified metabolites within these profiles hypothetically would be useful in noninvasive diagnostic modalities such as imaging with magnetic resonance spectroscopy
and positron emission tomography so that invasive testing such as brain biopsy and
resection can be avoided.

Methods
Study Design (First Study)
We conducted a prospective observational study in 15 patients ≥ 18 years with
aneurysmal subarachnoid hemorrhage, graded with modified Fisher score32 and Hunt and
Hess scale33. Aneurysms were clipped or coiled with external ventricular drains placed on
day of admission or during surgical intervention according to instructional guidelines.
Neurological examinations and transcranial Doppler sonography34 were performed daily
to assess for cerebral vasospasm35, which was confirmed with CT angiography or formal
catheter angiography. At the first year post-aSAH office visit, patients were evaluated
using the Glasgow Outcome Scale (GOS)36. The study was approved by the Yale New
Haven Hospital’s Institutional Review Board. Informed consent for this study was
obtained from either patients or their relatives at the time of cerebrospinal fluid
procurement.
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Daily CSF samples were collected from each patient while the ventriculostomy
was in place. All patients had CSF samples collected on admission. This was compared to
CSF from the first day that transcranial Doppler studies suggested at least moderate
vasospasm. This was confirmed at a minimum with CT angiography. For those patients
who had no radiographic vasospasm, CSF samples were selected on an average of postbleed day 6.

Sample Preparation for GC-TOF (First Study)
After collection, CSF samples were immediately frozen and stored at -80°C until
the time of simultaneous processing. For each sample, 5 µl of CSF were mixed with 1.0
mL of extraction solution (acetonitrile, isopropanol, and water in proportion 3:3:2).
Samples were vortexed for 10 seconds and shaken for 5 minutes at 4°C using an Orbital
Mixing Chilling/Heating Plate (Torrey Pines Scientific Instruments; Carlsbad, CA).
Samples were then centrifuged for 2 minutes at 14000 rcf. The whole aliquot was
evaporated using a Centrivap cold trap concentrator (Labconco, Kansas City, MO) to
complete dryness and then re-suspended with 450 µl of degassed 50% acetonitrile. After
being centrifuged for 2 minutes at 14000 rcf, the supernatant was removed, dried, and
submitted for derivatization.

GC-TOF Methodology (First Study)
All samples were processed simultaneously and analyzed using GC-TOF
according to published methodology in previously published studies37. An Agilent 6890
Gas Chromatograph (Agilent Technologies, Santa Clara, CA) with a Gerstel automatic

12
linear exchange and Gerstel cold injection system (Gerstel, Muehlheim, Germany) was
programmed with the following temperature settings: 50°C to 275°C final temperature at
a rate of 12 °C/s and hold for 3 minutes. The injection volume was 0.5 µl with an
injection speed of 10 µl/s on a splitless injector with 25 seconds of purge time.
The gas chromatograph separation columns used in this study were of a 10 m long
integrated guard column and a 30 m long, 0.25 mm Rtx-5Sil MS column (Restek,
Bellefonte, PA) with a 0.25 µm 95% dimethyl/5% diphenyl polysiloxane film. The
separations parameters consisted of 99.9999% ultra-pure helium with built-in purifier
(Airgas, Radnor, PA) as the carrier gas at a constant flow rate of 1 mL/minute. Oven
temperature was held at a constant 50°C for 1 minute and then increased by 20°C per
minute up to 330°C, which was then held for 5 minutes.
The mass spectrometer used was a Leco Pegasus IV time-of-flight mass
spectrometer with Leco ChromaTOF software (LECO Corporation, St. Joseph, MI). All
samples were introduced at a transfer line temperature of 280°C. Electron impact
ionization was set at 70 eV with a 250°C ion source temperature. For quality control, four
calibrates and two blank samples were used in each run.

Data Processing (First Study)
Data processing followed previously published methodologies37. Using guidelines
set by the Metabolomics Standards Initiative38, GS/MS were annotated only if both
retention index and mass spectra matched. The signals reported were then exported using
the BinBase database, consisting of quantification ion, retention index, unique database
identifier, and a complete mass spectrum string. The result files were transformed by
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calculating the sum of all structurally identified compounds for each sample and by
dividing all data with each sample by the corresponding metabolite sum; this value was
then multiplied by a constant factor to obtain values without decimal places.

Data Analysis and Statistics (First Study):
All statistical analysis was performed using “R” version 3.2.3, a modular opensource programming suite (http://cran.r-project.org/). Data visualization was conducted
with the “ggplot2” R-package. Metabolite levels at both time points were compared using
principal component analysis and paired sample T-test with fold change threshold > 0.5.
Metabolites levels at each time points were correlated with GOS using Pearson
correlation. The significance threshold was p<0.05 with false discovery rate and
Bonferroni corrections. The identified metabolite levels were compared with vasospasm
development, modified Fisher grade, and Hunt and Hess scale by Mann Whitney U test
or Pearson correlation. Metabolites that correlated with GOS were described with
receiver operating characteristic curves to predict patients who had low disability
(GOS=5) compared to moderate disability to death (GOS≤4).

Patient Cohort (Second Study)
All patients undergoing Gamma Knife radiosurgery at our institution sign consent
for the details of their radiosurgery treatment and subsequent clinical course to be entered
prospectively into a database. The names of patients who had to undergo surgical
resection following radiosurgery were retrieved retrospectively and any available tissue

14
from these patients was retrieved from pathology achieves for this project according to
institutional guidelines.

Collection and Pathologic Examination of Tissue Samples (Second Study)
All patients in this study had brain metastases that were treated with GKRS at the
Yale Gamma Knife Center using the Leksell Gamma Knife 4C machine with
radiosurgery dosing based on lesion volume as guided by RTOG-90-05 protcol39. At the
time of lesional regrowth as seen by gadolinium-enhanced magnetic resonance imaging
on follow-up imaging, each case was discussed at a multidisciplinary tumor board and
each patient was selected to undergo surgical resection for optimal control of their
regrowing lesions.
Immediately after surgical excision, all resected samples were bisected and
processed in two different ways. Half of the sample was processed into formalin and
paraffin for immediate surgical pathology diagnosis, while the other half was snap-frozen
in optimal cutting temperature (OCT) compound. During retrospective identification of
ideal radiation necrosis and recurrent tumor samples, sections of each sample from the
paraffin block and frozen sections from the OCT block were concurrently examined
histologically. Given that imaging changes after radiation can represent tumor regrowth,
radiation injury or a combination of both, each specimen intended for metabolomics
analysis was examined histologically first. Pure areas of radiation necrosis and pure areas
of tumor were then separated from the resected specimens by neuropathologist Alexander
Vortmeyer as shown in Figure 5. On histology, radiation necrosis was defined as three
concentric rings of tissue with innermost necrosis, a middle region of reactive gliosis with
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demyelination, and an outer ring of edema. As the distinguishing pathology, the middle
region of reactive gliosis in the absence of tumor cells was separated from the other
regions and sent for analysis after being matched to tumor sample of the same primary
tumor type.
Upon dividing the surgical samples into either radiation necrosis or tumor, tissue
samples were sectioned at -25°C to produce OCT-free 20-micron thick tissue flakes.
Only areas of each histological slide with uniform histologic results (either radiation
necrosis or recurrent tumor) were submitted for metabolomics analysis at the West Coast
Metabolomics Center (Davis, California). The research study described here was
performed with approval of Yale Pathology Tissue Services (YPTS Tissue Banking
Protocol HIC# 304025173).

Sample Preparation for GC-TOF (Second Study)
For each sample, 4 mg of tissue was weighed and added to 1.0mL of acetonitrile,
isopropanol, and water (3:3:2). The samples were homogenized using GenoGrinder and
centrifuged at 2500 rpm for 5 minutes. The samples were then evaporated in a Labconco
Centrivap cold trap concentrator and resuspended in 500 µl of 50% acetonitrile. After
being centrifuged for 2 minutes at 14000 rcf, the supernatant was removed, evaporated,
and submitted for two step derivatization with methoxyamine in pyridine followed by
silylation with MSTFA (N-Methyl-N-(trimethylsilyl) trifluoroacetamide).

GC-TOF Methodology (Second Study)
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The methodologies used were published in a previous study37. An Agilent 6890
Gas Chromatograph was equipped with a Gerstel automatic liner exchange system and a
Gerstel cold injection system with temperature program as follows: 50°C to 275°C final
temperature at a rate of 12 °C/s and hold for 3 minutes. Injection volume was 0.5 µl with
10 µl/s injection speed on a splitless injector with purge time of 25 seconds.
The gas chromatograph separation column consisted of a 30 m long, 0.25 mm
Rtx-5Sil MS column with a 0.25 µm 95% dimethyl/5% diphenyl polysiloxane film and
an additional 10 m integrated guard column. For the separation parameters, 99.9999%
ultra pure helium with built-in purifier was used as a carrier gas at a constant flow of 1
mL/minute with oven temperature held constant at 50°C for 1 minute then increased by
20°C per minute to 330°C, which was held constant for 5 minutes.
A Leco Pegasus IV time-of-flight mass spectrometer controlled using Leco
ChromaTOF software was used. The samples were introduced with a transfer line
temperature set at 280°C. Electron impact ionization occurred at 70 eV with an ion
source temperature of 250°C. Two blank samples and four calibrates were included in
each run for quality control.

Data processing (Second Study)
GC/MS peaks were annotated only if identified according to Metabolomics
Standards Intiative guidelines with both mass spectra and retention index recorded and
matched. All signals were exported by the BinBase database, which was reported by
quantification ion, a unique database identifier, retention index, and the complete mass
spectrum encoded as string.
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Result files were transformed by calculating the sum of all structurally identified
compounds for each sample and by dividing all data associated with a sample by the
corresponding metabolite sum. This value was multiplied by a constant factor to obtain
values without decimal places; intensities of identified metabolites with more than one
peak were summed to only one value in the transformed data set.

Statistical Analysis (Second Study)
Statistical testing was conducted using “R” version 3.2.3, a modular open-source
programming suite (http://cran.r-project.org/). A principal component analysis was
performed to check for discrimination accuracy between comparison groups using the
“ropls” R-package. A random forest analysis utilizing the 10,000 trees was performed to
obtain predictive accuracy metrics and a ranked list of metabolites based on importance
to the classification scheme. The random forest analysis was conducted using the
“randomForest” R-package.
Univariate statistical analysis included the Mann-Whitney U test and fold change
between the comparison groups. Positive fold change values indicate elevated levels in
radiation necrosis whereas negative fold change values indicate elevated levels in tumor.
Statistical significance defined as p < 0.05 and fold change > 0.5. An unsupervised
hierarchical clustering analysis was performed to obtain metabolomics subtypes within
global metabolomics profiles to ascertain purported metabolic pathways, conducted using
the “heatmap.plus” R-package. All data visualization was performed with the “ggplot2”
R-package.
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Author Contributions (Both Studies)
Alex Lu performed or was involved in the following:
• First Study: study design, all statistical analysis, all figure and table generation,
manuscript drafting, and manuscript revisions.
• Second Study: study design, all statistical analysis, all figure and table generation,
manuscript drafting, and manuscript revisions.
GC-TOF was performed by the West Coast Metabolomics Center (UC Davis, Davis,
California) through their commercial metabolomics service.

Results
Patients and Descriptive Data (Study 1):
We enrolled fifteen patients with high-grade aneurysmal subarachnoid
hemorrhage, defined by modified Fisher scale 3 or 4 (Table 1). The mean age was
55.73±16.98. Eleven (73%) patients were female. The mean Hunt and Hess score was
3.6±0.91. Nine patients (60%) developed vasospasm during their post-aSAH course. At
one-year follow-up, 9 (60%) patients had no or low disability with Glasgow Outcome
Score=5. Average post-bleed day collection at admission and during hospitalization were
1.06±0.7 and 5.53±2.0 respectively (Table 2).

Global Metabolite Changes:
GC-TOF identified 97 metabolites with known chemical structures. In a principal
component analysis, the first and second principal components captured 19.4% and
14.5% respectively of the data variance (Figure 1). Sixteen metabolites (12 after
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Bonferroni correction) changed significantly between the two time points (Table 3 and
Figure 2A). In all these metabolites measured during hospitalization, the changes were
magnified if patients had intraventricular hemorrhage and/or parenchymal extension
(modified Fisher grade 4 vs 3), as shown in Table 3 and Figure 2B. Of the identified
metabolites, no significant correlations were found after multiple correlation statistical
correction with vasospasm development or Hunt and Hess scale.

One Year Outcome Predictors:
When correlating metabolite levels at each time point and GOS score, 6
metabolites measured during hospitalization correlated with GOS score (Table 4). 2hydroxyglutarate was significant after Bonferonni correction (p=4.54e-4, Pearson=-0.79).
Lower levels of all 6 metabolites correlated with better one-year outcomes post
aneurysmal subarachnoid hemorrhage. When predicting patients who had no or low
disability (GOS = 5), 2-hydroxyglutarate had a sensitivity of 0.89 and specificity of 0.83.
The receiver operating characteristic curve of 2-hydroxyglutarate had an area-undercurve value of 0.85 (Figure 3A). The receiver operating characteristic curves for
tryptophan, glycine, proline, isoleucine, and alanine had area-under-curve values of 0.67,
0.81, 0.80, 0.72, and 0.78 respectively.
At time of admission, 2-hydroxyglutarate levels in patients with GOS=5 and
GOS≤4 were not statistically different (p=0.328) (Figure 3B). However, from time at
admission to time during hospitalization, 2-hydroxyglutarate levels in patients with
GOS=5 trended to decrease (p=0.22, fold change=-0.18) whereas 2-hydroxyglutarate
levels in patients with GOS≤4 trended to increase (p=0.143, fold change=0.16), as shown
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in Figure 4. In alpha-ketoglutarate, the precursor to 2-hydroxygluarate, alphaketoglutarate levels in patients with GOS=5 also trended to decrease (p=0.337, fold
change=-0.087) whereas alpha-ketoglutarate levels in patients with GOS≤4 trended to
increase (p=0.278, fold change=0.32), as shown in Figure 4.

Patient and Pathological Tissue Characteristics (Study 2)
Patient demographics and pathological specimen characteristics are summarized
in Table 5 and Table 6. The average age of patients at the time of biopsy was 53.9 years.
Two patients (20%) were male, and 8 were female (80%). Of the 10 patients, 4
contributed only radiation necrosis specimens, and 3 contributed only tumor specimens; 3
patients contributed both radiation necrosis and tumor specimens. As shown in Figure 5,
tumor samples consisted of three primary tumor types: melanoma, breast, and non-small
cell lung cancer (NSCLC). These tumor types represent the most common primary sites
for central nervous system metastases.

Global Metabolite Analysis (Study 2)
Our protocol applied GC-TOF for pathologically confirmed radiation necrosis and
recurrent tumor samples. In total, we identified 141 metabolites that could be confidently
correlated to known biochemical structures. A principal component analysis of the global
metabolite profiles suggests high discrimination accuracy between the comparison
groups, shown in Figure 6A. The variance of the first and second principal component
were 43.83% and 24.86% respectively.
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A random forest analysis yielded an overall predictive accuracy of 78.57%. The
random forest analysis also produced a ranked list of metabolites to distinguish the
comparison groups. The top 25 metabolites are shown in Figure 6B.

Univariate Statistical Analysis of Identified Metabolites (Study 2)
Of the 25 metabolites identified with the random forest analysis, 17 metabolites
had levels that were significantly different between radiation necrosis and tumor samples
(p < 0.05 by Mann Whitney U test as shown in Table 7). These metabolites included
alpha-tocopherol, proline, citric acid, gamma-tocopherol, UDP-glucuronic acid,
butyrolactam, 2,5-dihydroxypyrazine, arachidonic acid, elaidic acid, taurine, UDP-Nacetylglucosamine, ribitol, adenosine-5-monophosphate, beta-sitosterol, conduritol-betaexpoisde, lauric acid, and putrescine. Of these metabolites, 6 metabolites were increased
in tumor, and 11 metabolites were increased in radiation necrosis; all metabolites had an
absolute fold change > 0.5 between comparison groups.

Metabolite Cluster Analysis (Study 2)
An unsupervised hierarchical clustering analysis of the identified 17 metabolites
shows three distinct clusters of metabolites that discriminate the comparison groups of
radiation necrosis vs. recurrent tumor (Figure 7). The three clusters represent increased
metabolism (elevated in tumor), fatty acid products (elevated in radiation necrosis), and
antioxidants/cofactors (elevated in radiation necrosis). The two metabolites that were
most significantly elevated in radiation necrosis compared with recurrent tumor were
alpha-tocopherol and citric acid. The two metabolites most elevated in recurrent tumor
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compared with radiation necrosis were proline and UDP-glucuronic acid). Boxplots of
the metabolite levels between comparison groups are shown in Figure 8. The receiveroperating curve of these metabolites have area-under-curve values of 1.00, 0.92, 0.94,
and 0.93 respectively.

Analysis of Metabolites Currently Used in MR spectroscopy and PET (Study 2)
N-acetyl aspartate (NAA) along with creatine and choline are the metabolites
currently used in MR spectroscopy for identification of radiation necrosis versus recurrent
tumor. Of these 3 metabolites, only NAA was identified with this study’s methodologies.
NAA trended but was not found to be significantly elevated in radiation necrosis compared
to tumor (p = 0.073, fold change 1.36). The boxplot and ROC curve of NAA with AUC
value of 0.8.
In PET, analogs of glucose, are most commonly used although amino acids such
methionine, phenylalanine and tyrosine have been studied at a few dedicated centers.
Glucose and the individual amino acids were identified with this study’s methodologies.
The first quartile, median, and third quartile values of glucose trended to be higher in
tumor compared to radiation necrosis but did not reach statistical significance (p = 0.53).
Methionine, phenylalanine, and tyrosine also trended to be elevated in tumor compared
radiation necrosis but again did not reach statistical significance (p = 0.62, 0.71, and 0.80,
fold change = -0.17, -0.36, and -0.13 respectively). The receiver operating characteristic
AUC values of glucose, methionine, phenylalanine, and tyrosine were 0.61, 0.59, 0.55,
and 0.57 respectively.

23
Discussion
Study 1
Therapies that reduce cerebral vasospasm incidence have not produced better
patient outcomes19. Successful biomarker identification in aneurysmal subarachnoid
hemorrhage has been limited, and none are currently used in a clinical setting. In this
exploratory study, we report the first use of untargeted metabolomics to screen large
numbers of metabolites without the bias of theory-driven targeted metabolomics studies
using cerebrospinal fluid in aneurysmal subarachnoid hemorrhage patients. This is also
the first research study to implicate 2-hydroxyglutarate, a known biomarker of
physiologic hypoxia in all human cells including neurons, in aneurysmal subarachnoid
hemorrhage pathogenesis.
Our analysis identified metabolites (primarily free amino acids) that changed
significantly during hospitalization; these changes were magnified if patients had
intraventricular hemorrhage and/or parenchymal extension (modified Fisher grade 4 vs.
grade 3). Similar changes in free amino acids have been identified in venous blood40 of
aneurysmal subarachnoid hemorrhage patients but were not associated with modified
Fisher grade. While the cause of these metabolomics changes are unknown, two possible
explanations are that these metabolites may be markers of increased blood breakdown
and/or increased catabolism.
Our analysis also revealed a 6-metabolite panel that predicted long-term outcome
independent of cerebral vasospasm development. Four of these metabolites (tryptophan,
proline, isoleucine, alanine) significantly increased from time at admission to time during
hospitalization. Glycine and proline are major components of collagen; induction of
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meningeal collagen synthesis has been shown to be a pathologic hallmark of
subarachnoid hemorrhage41.
2-hydroxyglutarate can measured in vivo using MR spectroscopy42 and is
produced from alpha-ketoglutarate. 2-hydroxygluarate exists as two enantiomers: L-2hydroxyglutarate and D-2-hydroxyglutarate. While D-2-hydroxyglutarate has been linked
to glioma pathogenesis via mutant isocitrate dehydrogenase43, L-2-hydroxyglutarate was
recently implicated in all human cells as a universal physiologic adaptive response to
hypoxia44,45. Human neuronal cells have been specifically shown to preferentially
produce high levels of L-2-hydroxyglutarate in response to hypoxic stress46. High levels
of L-2-hydroxyglutarate inhibit alpha-ketogluarate-dependent dioxygenases to regulate
histone methylation levels and mitigate cellular reductive stress by inhibiting glycolysis
and electron transport44,45.
2-hydroxyglutarate has not been previously linked to stroke or stroke outcomes.
We demonstrated that 2-hydroxyglutarate levels measured during hospitalization
correlated with degree of recovery and could predict patients who had low disability at 1
year post-aSAH. While patients had similar levels of 2-hydroxyglutarate at admission, 2hydroxyglutarate trended to increase in patients with moderate disability to death and
trended to decrease in patients with low disability; these findings were mirrored in alphaketogluarate. Combined with previous literature, our results suggest that 2hydroxyglutarate may be a marker of tissue hypoxia induced by global ischemia in
aSAH.
This preliminary exploratory study has several limitations. The sample size and
collection days of CSF were limited with only 15 patients with cerebrospinal fluid
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metabolites levels measured at 2 time points reported. Future studies would benefit from
cerebrospinal fluid measurements every day post-aSAH, allowing for increased
resolution of metabolite levels post-aSAH. The addition of serum measurements of
metabolite levels would also provide insight on global effects of aSAH and the
relationship between serum and cerebrospinal fluid metabolite levels. Additional
limitations include variability between cerebrospinal fluid collection days and no chiral
discrimination of metabolites. Because this study design utilized untargeted
metabolomics using GC-TOF, the data can only provide relative quantification so
metabolites of interest would need to be measured using methods that provides SI units,
which would be necessary to validate a clinically useful biomarker.
These results will need to be validated in a larger prospective study with increased
temporal resolution and chiral analysis to differentiate the different enantiomers of 2hydroxyglutarate. Knowledge about the specific metabolic changes in the brain during
the course of aneurysmal subarachnoid hemorrhage may also provide important new
insight into the pathophysiology of aneurysmal subarachnoid hemorrhage. In clinical
practice, measurement of 2-hydroxyglutarate could be investigated as potential biomarker
of ischemia after aneurysmal subarachnoid hemorrhage.
Overall, this is the first study to use untargeted metabolomics of CSF samples
collected from aSAH patients for acute disease monitoring and long-term outcome
assessments. The metabolites identified improve the current understanding of aSAH
pathogenesis. 2-hydroxyglutarate may be used to predict patient outcomes and may
represent a biomarker of global ischemia.
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Study 2
A non-invasive method to differentiate radiation necrosis from recurrent tumor
remains elusive but much needed today as the clinical use of radiosurgery increases47 and
patient survival continues to lengthen48. This study aimed to evaluate currently available
imaging metabolites and validate their use specifically in differentiating radiation
necrosis and metastatic tumor. In addition, this study aimed to identify novel metabolites
that may serve as alternative in vivo biomarkers for imaging that would potentially
outperform currently used metabolite imaging biomarkers.
In utilizing in vivo metabolite biomarkers, MR spectroscopy and PET would be
the most promising imaging modalities. Current MR spectroscopy methods examine
choline/creatine (Cho/Cr) and choline/N-acetyl aspartate (Cho/NAA) ratios. In this study,
we were only able to measure NAA and therefore we were not able to make conclusions
about the validity of using these ratios.
Current PET radiotracer analogs include glucose, methionine, phenylalanine, and
tyrosine in the form of fluorodeoxyglucose (FDG), L-methyl-11C-methionine (11C-MET),
3,4-dihydroxy-6–18F-fluoro-L-phenylalanine (18F-FDOPA) and O-2-18F-fluoroethyl-Ltyrosine (18F–FET) respectively. For all these metabolites, the underlying assumption is
that tumor is more metabolically active than radiation necrosis and accumulates higher
levels of these metabolites. FDG-PET has been the most studied but suffers from wide
ranges of reported sensitivities (65%-81%) and specificities (40%-94%)49 depending on
the institution and protocol used. Our results indicated that these 4 metabolites trended to
be elevated in tumor compared to radiation necrosis, supporting the currently used PET
methodology. However, the ability to discriminate between radiation necrosis and tumor
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appear to be suboptimal compared to that of other candidate metabolites identified in our
study.
We identified 17 novel metabolites that may have higher diagnostic potential if
they can be translated into imaging studies. Our results suggest that radiation necrosis had
elevated levels of fatty acids and antioxidant/cofactor metabolites whereas tumor had
elevated energy metabolism markers.
In radiation necrosis, demyelination and cell death may result in increased fatty
acid products; we identified lauric acid, ribitol, putrescine, putyrolactam, arachidonic
acid, and elaidic acid as potential biomarkers within this group. Previous studies have
found that oligodendrocytes are extremely sensitive to radiation50,51. In addition, MR
spectroscopy of radiation necrosis often contains a large lipid peak, but no studies have
resolved the involved metabolites50,52,53. The identified biomarkers in this study may
contribute to this peak.
In addition, radiation necrosis tissue may mobilize elevated levels of antioxidants
in response to oxidative stress and increased cell death within the local cellular niche.
Our study identified the metabolites gamma-tocopherol, alpha-tocopherol, beta-sitosterol,
citri acid, and conduritol-beta-epoxide as candidate biomarkers. While it is uncertain why
these metabolites were elevated in radiation necrosis, one external explanation could be
bias due to unreported patient oral supplementation. However, given that 3 patients
contributed to both tumor and radiation necrosis samples, the likelihood of this bias is
low.
Tumor is more anabolically active than normal tissue and likely more active than
radiation necrosis; we found that tumor has increased levels of adenosine-5-
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monophosphate, taurine, 2,5-dihydroxypyrazine, proline, UDP-glucronic acid, and UDPN-acetyglucosamine. Taurine has been identified to be elevated in tissue samples of lung
cancer tissue compared to paracancinomous tissue54. In addition, proline biosynthesis has
been shown to augment tumor cell growth and aerobic glycolysis55. UDP-glucuronic acid
and UDP-N-acetylglucosamine are both used by glucuronsyltransferase and
glycosyltransferases reactions. Using UDP-N-acetylglucosamine as a substrate, multiple
tumor types including breast, prostate, lung, liver colon, and bladder cancer have
increased O-linked-β-N-acetylglucosamine modifications on intracellular proteins
through the mTOR/MYC pathway56. Elevated levels of UDP-N-acetylglucosamine have
also been found in human lung adenocarcinoma compared to nonmalignant tissue57 as
well as in human melanoma cells implanted in mice58.
There are several limitations to this study. First, due to the low number of
available tissue samples, no metabolites in the univariate statistical analysis reached
significance with Bonferroni correction (significance threshold p = 3.54e-4). Although
over 50 samples of resected tissue was examined, only 7 samples of radiation necrosis
and 7 samples of recurrent tumor were pure enough in each pathology type to fit the
criteria for study. This study was originally performed as a proof of concept study to
determine if unique metabolites could be identified for radiation necrosis versus tumor.
To the authors’ knowledge, the study design of using flash frozen neural tissue postresection in combination with metabolomics analysis has not been reported in the
literature.
While several metabolites have been identified, the validity of our results still
needs to be confirmed by further studies that include a larger sample size and a larger
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variety of metastatic tumors. In addition, there are no data from this study to suggest that
similar metabolites should be used to differentiate primary brain tumors from radiation
necrosis. Second, this study does not provide any correlation with currently available
imaging changes. While this would be the ultimate goal of solving the issue of
differentiating radiation necrosis and recurrent tumor, the metabolites identified in the
present would have to be translated into MR spectroscopy or PET imaging to become
clinically useful. Third, this study does not address possible metabolite changes in
pseudo-progression as it remains unclear if the pathophysiology of early post-radiation
change such as pseudo-progression is the same as the delayed changes of radiation
necrosis.
We acknowledge that these data are preliminary and that future work must be
performed to validate these metabolites in combination with the development of in vivo
neuroimaging modalities. If non-invasive imaging modalities can be developed
specifically for the metabolites identified in this study, however, this may be the first step
to robustly solving the current dilemma of distinguishing radiation necrosis and recurrent
tumor after radiosurgery.
In summary, this study reports the first tissue-based untargeted metabolomics
analysis of examining differential metabolic profiles of radiation necrosis versus tumor.
The results identify multiple candidate metabolites that may be used with imaging
modalities such as MR spectroscopy and PET imaging for differentiating radiation
necrosis and tumor; these candidate metabolites may have much higher binary
classification test results compared to those of currently used metabolites in MR
spectroscopy and PET as suggested by tissue-based metabolomics results of the present
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study. Although promising, a prospective study using the identified metabolites with
radiographic techniques will be needed to test the applicability of these study results. If
such study were successful, the need to ability to differentiate radiation necrosis and
recurrent tumor using non-invasive imaging would eliminate the need for surgical
resection in cases presenting without mass effect on local structures.

Conclusion:
These studies demonstrate the application of metabolomics to issues of
neurosurgical importance. Future studies within neurosurgery may focus on the fields of
traumatic brain injury, epilepsy, and brain cancer. Metabolomics is powerful tool to
analyze the biochemical profile of any biological sample. The scale of high-throughput
metabolomics is rapidly increasing. As metabolomics technology advances and
workflows become optimized, the three areas of high-throughput metabolomics will
increase cohort size, temporal resolution, and spatial resolution in future studies17. More
patients will be included in these studies to allow for higher statistical power. The
number of metabolites that can identified simultaneously will increase and the time it
takes to analyze the high-throughput data will decrease. Finally, current metabolomics
studies examine homogenized cell extracts or biofluids such as serum and cerebrospinal
fluid. Future studies will be able to sample metabolome of single cells within
subpopulation of interest.
The future of metabolomics will also rely on its integration with the ‘omics fields
(genomics, transcriptomics, and proteomics) into a streamlined multi-omics platform.
While the technology for combining these tools remains rudimentary, the multi-omics
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approach has the potential to change the landscape of biomarker identification, drug
discovery, and personalized medicine.
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Figure References and Legends
Figure 1: Principal component analysis of CSF samples collected at admission vs. during
hospitalization.
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Figure 2: Metabolites significantly change from time at admission to time during
hospitalization
A. 16 metabolites significantly change between time at admission to time during
hospitalization.
B. Of the 16 metabolites measured at hospitalization, changes were magnified with
higher modified Fisher grade (4 vs. 3). Nine of these metabolites had p<0.05.
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Figure 3: Relative 2-hydroxygluarate levels and receiver operating characteristic curve of
2-hydroxyglutarate at predicting patients with low disability (GOS=5) at 1-Year PostaSAH. 3A.
•

For patients with GOS=5, 2-hydroxyglutarate trended to decrease whereas for
patients with GOS≤4, 2-hydroxyglutarate trended to increase. 3B. Area-undercurve value of 0.85 for the receiver operating characteristic curve of 2hydroxyglutarate.
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Figure 4: Patients with low disability (GOS=5) trend to have lower levels of alphaketoglutarate and 2-hydroxyglutarate whereas patients with higher disability (GOS≤4)
trend to have higher levels of alpha-ketoglutarate and 2-hydroxyglutarate during aSAH
hospital course
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Figure 5: Histology of Radiation Necrosis and Tumor
•

The identity of each flash frozen sample was confirmed histologically. Radiation
necrosis at 200x (A) & 400x (B) magnification, H&E. Radiation necrosis was
defined as inflammatory demyelination and reactive gliosis in the absence of
tumor cells. Recurrent non-small cell lung cancer at 200x (C) & 400x (D)
magnification, H&E. Metastatic tumors from various primary tumors were also
identified histologically.
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Figure 6: Principal Component Analysis Plots and Random Forest Analysis Shows High
Discrimination Accuracy Between Radiation Necrosis and Tumor
A) Principal component analysis score plot showing differential variance between
tumor and radiation necrosis as well as primary tumor types.
B) Random forest analysis identifies a ranked list of metabolites for classification of
tumor versus radiation necrosis.
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Figure 7: Heatmap of Significant Metabolites Reveals Metabolic Signatures of Radiation
Necrosis and Tumor
•

An unsupervised hierarchical clustering analysis shows 3 distinct clusters of
metabolites that discriminate radiation necrosis and tumor. Metabolites that
represent increased metabolism were elevated in tumor. Metabolites that represent
fatty acid products and antioxidants/cofactors were elevated in radiation necrosis.
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Figure 8: Boxplots and Receiver Operating Characteristic Curves for Selected
Metabolites Discriminating Between Tumor and Radiation Necrosis
•

Selected metabolites provide a high degree of discrimination between tumor and
radiation necrosis according to the area-under-curve values of the receiver
operating characteristic curves.
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Tables.
Table 1: Patient demographics and characteristics
H&H = Hunt and Hess Scale; GOS = Glasgow Outcome Scale; A-Comm =
anterior communicating artery; P-Comm = posterior communication artery; VA =
vertebral artery; ICA = internal carotid artery; MCA = middle cerebral artery

Patient
aSAH Aneurysm Cerebral Modified
ID Age Gender Smoking Hypertension treatment
Site
Vasospasm Fisher H&H GOS
1

54

F

+

+

Coiling R P-Comm

+

4

4

5

2

24

M

+

−

Coiling

A-Comm

+

3

4

4

L VA

+

3

4

5

3

63

M

−

−

L VA
Closure

4

56

F

−

−

Coiling R P-Comm

+

4

4

5

5

48

M

+

+

Coiling

A-Comm

+

3

2

5

6

57

F

+

−

Coiling

A-Comm

+

4

3

1

7

49

F

−

+

Clipping A-Comm

+

4

3

5

8

40

F

+

−

Clipping A-Comm

+

3

3

5

9

68

M

+

+

Clipping A-Comm

+

3

3

5

10

28

F

+

−

Coiling

A-Comm

−

3

4

4

11

74

F

+

+

Clipping

L MCA

−

4

5

3

12

88

F

−

+

−

4

4

1

13

51

F

+

+

L Superior
Coiling Cerebellar
A-Comm, L
Supraclinoid
Coiling
ICA

−

3

2

5

14

68

F

+

−

Clipping

R MCA

−

4

5

5

15

68

F

−

+

Coiling

A-Comm

−

3

4

4
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Table 2: CSF collection listed by post-bleed day

Patient ID

Post-Bleed Collection Day Post-Bleed Collection Day
(At Admission)
(During Hospitalization)

1

1

4

2

0

5

3

2

3

4

1

6

5

2

4

6

1

7

7

2

5

8

0

9

9

1

4

10

1

6

11

1

5

12

0

3

13

2

6

14

1

10

15

1

6
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Table 3: Metabolites significantly change from time at admission to time during
hospitalization
*Significant after Bonferroni correction; KEGG ID = Kyoto Encyclopedia of
Genes and Genomes identifier; NS = Not Significant
Nominal p- Bonferroni
Value
Correction

Fold
Fold
Nominal pChange
Change Value (Fisher) (Fisher)

Metabolite

KEGG

phenylalanine

C00079

2.47E-05

*

1.37

5.91E-03

0.63

leucine

C00123

3.95E-05

*

1.75

2.89E-02

0.65

threonine

C00188

4.39E-05

*

1.67

NS

0.32

valine

C00183

7.10E-05

*

1.69

2.89E-02

1.63

tryptophan

C00078

7.22E-05

*

0.82

2.05E-02

1.45

serine

C00065

8.51E-05

*

0.58

NS

0.02

glycerol

N/A

8.92E-05

*

-0.96

NS

-0.04

1,5-anhydroglucitol

C07326

1.38E-04

*

-0.55

2.05E-02

-1.89

methionine
betamannosylglycerate

C00073

1.45E-04

*

1.34

4.01E-02

1.48

N/A

2.29E-04

*

-0.54

2.05E-02

-1.91

asparagine

C00152

4.31E-04

*

1.70

1.40E-02

1.83

tyrosine

C00082

5.15E-04

*

0.74

3.73E-03

1.43

lysine

C00047

1.08E-03

NS

0.75

NS

0.33

glutamine

C00064

1.10E-03

NS

0.54

NS

0.20

isoleucine

C00407

4.53E-03

NS

0.91

NS

0.46

proline

C00148

1.04E-02

NS

1.73

NS

2.12
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Table 4: Metabolites significantly correlate with 1-year outcome post-aSAH
*Significant after Bonferroni correction; KEGG ID = Kyoto Encyclopedia of
Genes and Genomes identifier; NS = Not Significant

Bonferroni
Correction

Pearson's
Correlation
Coefficient

Metabolite

KEGG ID

Nominal
p-Value

2-Hydroxyglutarate

C02630

4.54E-04

*

-0.79

Tryptophan

C00078

7.16E-04

NS

-0.774

Glycine

C00037

9.51E-04

NS

-0.762

Proline

C00148

1.24E-03

NS

-0.751

Isoleucine

C00407

1.61E-03

NS

-0.74

Alanine

C00041

2.2E-03

NS

-0.726
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Table 5: Patient Demographics
•

Radiation necrosis and tumor specimens were obtained from 10 patients who
underwent Gamma Knife radiosurgery
NSCLC: non-small cell lung cancer, WT: wild type

GKRS
Primary Tumor
until
Patient
Age at
Primary Subtype & Mutation Resection
ID
Sex Biopsy Tumor Type
Studies
(Days)
Medications at Time of Resection
Adenocarcinoma
(ALK WT, AKT WT,
BRAF WT, EGFR
WT, ERB2 WT,
Kefzol (1g), Decadron (10mg), Mannitol (25g), Alprazolam
KRAS WT, MEK1
(.5mg PRN), Chlorpheniramine-hydrocodone (8mg every 12
1
F
47
NSCLC
WT, PIK3CA WT)
295
hours), Colace
Ceftriaxone (1g), Vancomycin (1g), Mannitol (25g),
Adenocarcinoma
Decadron (10mg), Vitamin C (250mg BID), Citalopram
(ALK WT, EGFR
(10mg daily), Keppra (500mg BID), Zinc Sulfate (220mg
2
F
66
NSCLC
WT, KRAS Q16H)
181
daily)
Adenocarcinoma
(ALK WT, AKT1
Acetaminophen (650mg every 6 hours), Acidophilus (1 day),
WT, BRAF WT,
Amlodipine (5mg), Bromday drops, Lactaid, Levothyroxine
EGFR WT, ERBB2
(150mcg daily), Lorazepam (.25mg PRN), Omeprazole
WT, KRAS WT,
(50mg daily), Sertraline (50mg daily), Timolol drops, Kefzol
MEK1 WT, PIK3CA
(1g), Keppra (500mg), Decadron (10mg), Mannitol (50g),
3
F
71
NSCLC
WT, ROS1 WT)
496
Lasix (20mg)
Adenocarcinoma
(EGFR WT, BRAF
WT, AKT WT,
4
F
50
NSCLC
MEK1 WT)
99
Kefzol (1g), Mannitol (25g), Lasix (40mg), Decadron (10mg)
Kefzol (1g), Decadron (10mg), Mannitol (25g), Vemurafenib
(750mg BID), Multivitamin, Omeprazol (20mg daily),
5
F
40
Melanoma
BRAF V600E
98
Keppra (150mg BID)

-1*

Kefzol (1g), Decadron (10mg), Mannitol (25g), Vitamin D
(1000U daily)
Vitamin C (1000mg daily), Colace (100mg daily),
Metoprolol (50mg daily), Ondansetron (8mg PRN),
Valsartan-hydrochlorothiazide (320mg daily), Vitamin D
(50,000 units weekly). Kefzol (1g), Mannitol (25g), Lasix
(20mg), Decadron (10mg)
Decadron (10mg), Kefzol (1g), Keppra (500mg),
Trastuzumab (every three weeks), Tykerb (250mg daily),
Ativan (1mg PRN), Glycolax, Zolpidem (PRN), Insulin
aspart (dates unclear)
Kefzol (1g), Decadron (10mg), Mannitol (25g), Pantoprazole
(40mg daily)

517

Kefzol (1g), Mannitol (.5g/kg), Decadron (10mg), Lasix
(20mg)

6

M

57

Melanoma

BRAF WT

76

7

F

66

Breast

ER+, PR+, HER2+

-8*

8

F

50

Breast

ER-, PR-, HER2
Equivocal

1604

9

M

35

Melanoma

10

F

57

NSCLC

BRAF V600E
Adenocarcinoma
(KRAS G12V, EGFR
WT)
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Table 6: Pathology Characteristics
•

Multiple primary tumor types were analyzed in an attempt to generalize our
findings. Seven samples of tumor were compared to 7 samples of demyelinating
radiation necrosis.
*Two samples of tumor included for metabolomic analysis were not irradiated
prior to resection; these patients underwent GKRS after resection
NSCLC: non-small cell lung cancer, WT: wild type

Specimen ID

Patient ID Primary Tumor Type

Pathology

Biopsy Location

1

1

NSCLC

Recurrent Tumor

Frontal

2

1

NSCLC

Radiation Necrosis

Frontal

3

2

NSCLC

Recurrent Tumor

Frontal

4

2

NSCLC

Radiation Necrosis

Frontal

5

3

NSCLC

Recurrent Tumor

Frontoparietal

6

3

NSCLC

Radiation Necrosis

Frontoparietal

7

3

NSCLC

Recurrent Tumor

Frontoparietal

8

4

NSCLC

Radiation Necrosis

Parietal

9

5

Melanoma

Recurrent Tumor

Frontal

10

6

Melanoma

Radiation Necrosis

Frontal

11

7

Breast

Metastatic Tumor

Cerebellar

12

8

Breast

Radiation Necrosis

Frontoparietal

13

9

Melanoma

Metastatic Tumor

Right Frontal

14

10

NSCLC

Radiation Necrosis

Temporal
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Table 7: Significant Metabolites Changes Between Radiation Necrosis and Tumor
•

Identified metabolites from RF analysis were analyzed using Mann-Whitney U
test. Positive mean fold indicates elevated levels in Radiation Necrosis; negative
fold change indicated elevated levels in tumor. KEGG database identifiers are
also displayed. In this analysis, 17 metabolites with known structures had p-value
< 0.05 and fold change > 0.5.
*KEGG ID: Kyoto Encyclopedia of Genes and Genomes identifier
NSCLC: non-small cell lung cancer
Metabolites

KEGG ID

Fold Change

Nominal P-Value

Alpha-Tocopherol

C02477

2.91

5.83E-04

Proline

C00148

-3.04

4.08E-03

Citric acid

C00158

1.15

6.99E-03

Gamma-Tocopherol

C02483

2.75

6.99E-03

UDP-Glucuronic Acid

C00167

-3.81

8.66E-03

Butyrolactam

C11118

5.89

1.11E-02

2,5-Dihydroxypyrazine

NA

-2.05

1.75E-02

Arachidonic Acid

C00219

1.63

1.75E-02

Elaidic Acid

C00712

0.86

1.75E-02

Taurine

C00245

-2.21

1.75E-02

UDP-N-Acetylglucosamine

C00043

-2.11

1.75E-02

Ribitol
Adenosine-5Monophosphate

C00474

1.94

2.13E-02

C00020

-0.87

2.62E-02

Beta-Sitosterol

C01753

1.18

2.62E-02

Conduritol-Beta-Epoxide

NA

2.13

3.79E-02

Lauric Acid

C02679

0.91

3.79E-02

Putrescine

C00134

1.47

3.79E-02

